APA (7th ed.) Citation

C, L., GF, A., BM, B., A, B., CL, B., I, C., . . . KV, K. (2026). Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial. Journal of hepatology, 84(1), 74. https://doi.org/10.1016/j.jhep.2025.04.025

Chicago Style (17th ed.) Citation

C, Levy, et al. "Safety and Efficacy of Elafibranor in Primary Sclerosing Cholangitis: The ELMWOOD Phase II Randomized-controlled Trial." Journal of Hepatology 84, no. 1 (2026): 74. https://doi.org/10.1016/j.jhep.2025.04.025.

MLA (9th ed.) Citation

C, Levy, et al. "Safety and Efficacy of Elafibranor in Primary Sclerosing Cholangitis: The ELMWOOD Phase II Randomized-controlled Trial." Journal of Hepatology, vol. 84, no. 1, 2026, p. 74, https://doi.org/10.1016/j.jhep.2025.04.025.